Ivanna Tsykhulyak, APRN
Primary Care · Waterbury, CTNPI 1083290423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$704
- Bayer$662
- Boehringer Ingelheim$376
- Novo Nordisk$353
- AstraZeneca$249
- Amgen$197
- plus $938 from 16 others
What the payments were for
- Food & beverage$3,43199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $704 |
| Bayer | 44 | $662 |
| Boehringer Ingelheim | 32 | $376 |
| Novo Nordisk | 27 | $353 |
| AstraZeneca | 10 | $249 |
| Amgen | 11 | $197 |
| QOL Medical, LLC | 8 | $188 |
| Viatris Specialty LLC | 10 | $135 |
| GSK | 6 | $114 |
| Lilly USA, LLC | 4 | $70 |
| Mylan Specialty L.p. | 3 | $63 |
| Astellas Pharma US Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Antares Pharma, Inc. | 2 | $50 |
| Corcept Therapeutics | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $37 |
| Lundbeck LLC | 2 | $35 |
| GRT US Holding, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,478 in reported general payments places this provider in the 90th percentile of 111 primary care providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $99,772 |
| JardianceEmpagliflozin | 48 | $72,651 |
| LinzessLinaclotide | 78 | $66,293 |
| JanuviaSitagliptin Phosphate | 34 | $44,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $39,508 |
| MounjaroTirzepatide | 26 | $31,287 |
| RybelsusSemaglutide | 15 | $25,734 |
| KerendiaFinerenone | 18 | $24,500 |
| EliquisApixaban | 30 | $22,405 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $13,440 |
| GemtesaVibegron | 12 | $9,153 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,170 |
| LyricaPregabalin | 12 | $6,663 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,541 |
| Testosterone | 36 | $4,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $353 | $125,506105 claims |
| Boehringer IngelheimJardiance | $376 | $72,65148 claims |
| AbbVieLinzess, Synthroid | $704 | $67,51791 claims |
| GSKTrelegy Ellipta | $114 | $39,50851 claims |
| Lilly USA, LLCMounjaro | $70 | $31,28726 claims |
| BayerKerendia | $662 | $24,50018 claims |
| AstraZenecaBreztri Aerosphere | $249 | $7,17011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 primary care providers in Connecticut.
Other primary care in Waterbury
- Kate RooneyWaterbury$291
- Kelly NolinEnfield$16K
- Deanna BallardDanbury$7K
- Jacqueline VelezBridgeport$7K
- Joyce WallHamden$5K
- Catherine KrenickyPawcatuck$5K
- Christopher AndersonGroton$5K
- Carolyn BrownMiddlebury$4K
- Rosaleen GalvinBridgeport$3K
- Erica SeebeckWilton$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.